Surface Oncology
50 Hampshire Street, 8th Floor
Cambridge
Massachusetts
02139
United States
Tel: 617-655-5030
Website: https://www.surfaceoncology.com/
About Surface Oncology
We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families.
Stock Symbol: SURF
64 articles with Surface Oncology
-
Surface Oncology to Participate in the 2021 Annual Cowen IO Next Summit
11/8/2021
Surface Oncology today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the upcoming Cowen Fifth Annual IO Next Summit on Monday, November 15, 2021 at 12:45 p.m. ET.
-
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2021
11/4/2021
Surface Oncology today reported financial results for the third quarter 2021, and provided a corporate update on recent highlights and anticipated near-term milestones.
-
Surface Oncology to Present Preclinical Data for Lead Clinical Programs at the Society for Immunotherapy of Cancer 2021 Annual Meeting
11/2/2021
Surface Oncology today announced that scientific posters sharing preclinical data will be presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting, to be held virtually and at the Walter E. Washington Convention Center in Washington, D.C. November 10-14, 2021.
-
Surface Oncology Announces New Randomized Phase 2 Clinical Study Evaluating SRF388 in Patients with First-Line Hepatocellular Carcinoma in Clinical Collaboration with Roche
10/4/2021
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced details about its plan to initiate a randomized Phase 2 clinical study evaluating SRF388, a potential first-in-class antibody against IL-27, in combination with Roche’s atezolizumab and bevacizumab, in patients with treatment-naïve hepatocellular carcinoma.
-
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2021
8/5/2021
Surface Oncology today reported financial results and corporate highlights for the second quarter 2021, and provided an update on anticipated corporate milestones.
-
BioSpace Movers & Shakers, July 9
7/9/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Surface Oncology Appoints Denice Torres to Board of Directors
7/8/2021
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Denice Torres will join the company’s board of directors.
-
Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a Novel Combination in Patients with Advanced Treatment-naïve Hepatocellular Carcinoma
6/4/2021
Surface Oncology announced a clinical trial collaboration with Roche to evaluate SRF388, Surface’s investigational anti-IL-27 antibody, in combination with Roche’s atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma.
-
SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monotherapy Activity in Data Presented at American Society of Clinical Oncology Annual Meeting
6/4/2021
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced the presentation of new data from the ongoing Phase 1 studies of SRF388 and SRF617.
-
Surface Oncology to Present Clinical Updates for SRF388 and SRF617
4/28/2021
Company to Hold Webcast to Review Data from Ongoing SRF388 and SRF617 Phase 1 Clinical Studies on Friday, June 4th at 8:00 a.m. ET
-
Surface Oncology Expands Leadership Team with Key Executive Appointment and PromotionsHenry Rath announced as chief business officer, Alison O’Neill as chief medical officer and Jessica Fees as chief financial officer
4/27/2021
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today the appointment of Henry Rath as chief business officer, and the promotions of Alison O’Neill, M.D. to chief medical officer and Jessica Fees to chief financial officer.
-
Surface Oncology Named a 2021 Best Places to Work Company by Boston Business Journal
4/19/2021
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that it has been recognized by the Boston Business Journal as one of the Best Places to Work in 2021.
-
Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting
4/9/2021
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, will present preclinical findings supporting the company’s lead product programs, SRF388 (targeting IL-27) and SRF617 (targeting CD39). These data will be presented as part of the American Association for Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually April 10-15
-
Data on multiple oncology therapeutic programs are being unveiled ahead of the start of the annual American Association for Cancer Research meeting, which will be held virtually this year due to the ongoing COVID-19 pandemic.
-
Surface Oncology to Present Preclinical Data for Lead Product Programs at the American Association for Cancer Research Annual Meeting
3/10/2021
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced two scientific e-posters sharing updated preclinical data will be presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting, to be held virtually April 10-15 and May 17-21, 2021.
-
Surface Oncology to Collaborate with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
3/9/2021
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced it has entered into a clinical trial collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF388, an investigational antibody therapy targeting IL-27, with Merck’s KEYTRUDA®, the first anti-PD-1 therapy approved in the United States.
-
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2020
3/9/2021
New Collaboration with Merck Will Evaluate SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
-
Surface Oncology to Participate in Upcoming March Investor Conferences
2/24/2021
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation therapies targeting the tumor microenvironment, today announced that Rob Ross, M.D., incoming chief executive officer, will participate in the following virtual investor conferences: Cowen 41 st Annual Healthcare Conference, Monday, March 1, 2021, at 10:20 a.m. ET as part of the Novel IO panel. H.C. Wainwright Global Life Sciences
-
Surface Oncology to Participate in H.C. Wainwright Bioconnect 2021 Conference
1/11/2021
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Jeff Goater, chief executive officer, will participate in the upcoming H.C. Wainwright Bioconnect 2021 Conference, which will take place January 11–14.